Quantcast
Home > Quotes > CRVS

Corvus Pharmaceuticals, Inc. Common Stock (CRVS) Quote & Summary Data

CRVS 
$3.42
*  
0.06
1.79%
Get CRVS Alerts
*Delayed - data as of Jun. 24, 2019  -  Find a broker to begin trading CRVS now
Exchange:NASDAQ
Industry: Health Care
Community Rating:
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks

Key Stock Data

Best Bid / Ask
N/A / N/A
Today's High / Low
$ 3.45 / $ 3.3391
Share Volume
60,720
50 Day Avg. Daily Volume
67,872
Previous Close
$ 3.36
52 Week High / Low
$ 12.65 / $ 3.22
Market Cap
100,297,998
Annualized Dividend
N/A
Ex Dividend Date
N/A
Dividend Payment Date
N/A
Current Yield
0 %

Intraday Chart

Shares Traded

Share Volume:
60,720
50 Day Avg. Daily Volume:
67,872

P/E Ratio

P/E Ratio:
NE
Forward P/E (1y):
NE
Earnings Per Share (EPS):
$ -1.52

Trading Range

The current last sale of $3.42 is 6.21% Higher than the 52 week low.

Intraday Last 52 Weeks
High: $ 3.45 $ 12.65
 Low: $ 3.3391 $ 3.22

Company Description (as filed with the SEC)

We are a clinical stage biopharmaceutical company focused on the development and commercialization of precisely targeted oncology therapies. Since we began operations in November 2014, we have built a pipeline of five oncology programs Three of our programs are aimed at disabling cancer's ability to subvert immune attack by inhibiting adenosine in the tumor microenvironment or by blocking its production by tumors. Adenosine activates an immune checkpoint, the adenosine A2A receptor, that is used by the body to limit inflammation and immune responses. Adenosine accomplishes this by interacting with the A2A and A2B receptors expressed on several cells of the immune system; including TĀ­cells, natural killer ("NK") cells, macrophages, dendritic cells and myeloid derived suppressor cells, as well as other cells. We are developing small molecules that selectively inhibit the binding of adenosine to either A2A receptors or to A2B receptors.  ... More ...  



Risk Grade

Where does CRVS fit in the risk graph?


Risk Grade Scale

Nasdaq Official Price

Open Price:
$ 3.37
Open Date:
Jun. 24, 2019
Close Price:
$ 3.42
Close Date:
Jun. 24, 2019


Consensus Recommendation

Analyst Info